Immunohistochemical and molecular study of severe cervical dysplasia associated with HPV-83

Gynecologic Oncology

Volumn 105, Issue 1, 2007, Pages 252-255

  Albrecht, Valérie ^a   Chevallier, Anne ^b   Bongain, André ^a   Lefebvre, Jean Claude ^a   Giordanengo, Valérie ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b PASTEUR HOSPITAL   (France)

Author keywords

CIN; E6; HPV 83; Mutations

Indexed keywords

AMINO ACID; PROTEIN ANTIBODY; PROTEIN E6; PROTEIN P16INK4A; PROTEIN P53; ZINC FINGER PROTEIN;

AGED; AMINO ACID SEQUENCE; ANTIBODY LABELING; ARTICLE; CANCER RISK; CASE REPORT; CYTOLOGY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 83; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFECTION RISK; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; RELAPSE; SQUAMOUS EPITHELIUM; UTERINE CERVIX DYSPLASIA; VIRUS INFECTION; WART VIRUS;

AGED; BASE SEQUENCE; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR SEQUENCE DATA; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS;

EID: 33947407263     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.12.013     Document Type: Article

References (10)

1. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J. Clin. Virol. 19 1-2 (2000) 1-5
2. Brown D.R., Legge D., and Qadadri B. Distribution of human papillomavirus types in cervicovaginal washings from women evaluated in a sexually transmitted diseases clinic. Sex Transm. Dis. 29 12 (2002) 763-768
3. Schlecht N.F., Kulaga S., Robitaille J., Ferreira S., Santos M., Miyamura R.A., et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286 24 (2001) 3106-3114
4. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348 6 (2003) 518-527
5. Nakagawa S., Watanabe S., Yoshikawa H., Taketani Y., Yoshiike K., and Kanda T. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro. Virology 212 2 (1995) 535-542
6. Phelps W.C., Munger K., Yee C.L., Barnes J.A., and Howley P.M. Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J. Virol. 66 4 (1992) 2418-2427
7. Albrecht V., Chevallier A., Magnone V., Barbry P., Vandenbos F., Bongain A., et al. Easy and fast detection and genotyping of high-risk human papillomavirus by dedicated DNA microarrays. J. Virol. Methods 137 2 (2006) 236-244
8. Klaes R., Friedrich T., Spitkovsky D., Ridder R., Rudy W., Petry U., et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int. J. Cancer 92 2 (2001) 276-284
9. Brown D.R., McClowry T.L., Woods K., and Fife K.H. Nucleotide sequence and characterization of human papillomavirus type 83, a novel genital papillomavirus. Virology 260 1 (1999) 165-172
10. Slebos R.J., Kessis T.D., Chen A.W., Han S.M., Hedrick L., and Cho K.R. Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro. Virology 208 1 (1995) 111-120